Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers

Seitz,S.; Rick,F. G.; Schally,A. V.; Treszl,A.; Hohla,F.; Szalontay,L.; Zarandi,M.; Ortmann,O.; Engel,J. B.; Buchholz,S.

doi:10.3892/or.2013.2435

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers

Authors:
- S. Seitz
- F. G. Rick
- A. V. Schally
- A. Treszl
- F. Hohla
- L. Szalontay
- M. Zarandi
- O. Ortmann
- J. B. Engel
- S. Buchholz
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93053 Regensburg, Germany, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
Published online on: April 29, 2013 https://doi.org/10.3892/or.2013.2435
Pages: 413-418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In preclinical studies, antagonists of growth hormone-releasing hormone (GHRH) have demonstrated inhibitory effects on the growth of various types of cancers expressing the pituitary type of GHRH receptors (pGHRH-R) and/or its active splice variant 1 (SV1). In this study, we investigated the effectiveness of the treatment of MDA-MB-231 human triple-negative breast cancer (TNBC) with GHRH antagonist JMR-132 alone or in combination with docetaxel. Receptor expression in the MDA-MB-231 human breast cancer cell line was evaluated by reverse transcription-polymerase chain reaction (RT-PCR). Cell viability assays were performed on MDA-MB-231 cells treated with JMR-132, docetaxel or in combination. For studies in vivo, a subcutaneous nude mouse xenograft model was used. JMR-132 was administered s.c. at a dose of 10 µg/day and docetaxel at a dose of 10 mg/kg i.p. given on day 1 and 5. Similar regimens were used for the combination of both substances. At the end of the experiment, an mRNA-based human cancer pathway array including 84 major genes was performed on the tumor tissue of mice treated with JMR-132 to elucidate the mechanism of action of GHRH antagonists in vivo. The in vitro proliferation studies revealed that JMR-132 and docetaxel decreased the cell viability in a dose-dependent manner. The combination of both treatments produced a significantly greater inhibition of cell viability compared to the single agents. Treatment of nude mice bearing MDA-MB-231 xenografts with JMR-132 and docetaxel significantly (p<0.05) inhibited tumor growth by 46 and 50%, respectively. Treatment with the combination of JMR-132 and docetaxel led to an inhibition of tumor volume by 71.6% (p<0.001). Polymerase chain reaction array analysis revealed that JMR-132 interacts with signal transduction pathways involved in proliferation, apoptosis and angiogenesis. Our results suggest that GHRH antagonists in combination with taxanes may enhance the efficacy of treatment for patients with TNBC expressing the SV1 and/or the pGHRH receptor.

View Figures

View References

1	Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
2	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
3	Tischkowitz M, Brunet JS, Bégin LR, et al: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7:1342007. View Article : Google Scholar : PubMed/NCBI
4	Schally AV, Steelman SL and Bowers CY: Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med. 119:208–212. 1965. View Article : Google Scholar : PubMed/NCBI
5	Rick FG, Schally AV, Block NL, et al: Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA. 108:3755–3760. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kiaris H, Chatzistamou I, Papavassiliou AG and Schally AV: Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab. 22:311–317. 2011. View Article : Google Scholar : PubMed/NCBI
7	Rick FG, Szalontay L, Schally AV, et al: Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol. 187:1498–1504. 2012. View Article : Google Scholar
8	Bagnato A, Moretti C, Ohnishi J, Frajese G and Catt KJ: Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology. 130:1097–1102. 1992.PubMed/NCBI
9	Rick FG, Schally AV, Szalontay L, et al: Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA. 109:1655–1660. 2012. View Article : Google Scholar : PubMed/NCBI
10	Busto R, Schally AV, Braczkowski R, et al: Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept. 108:47–53. 2002. View Article : Google Scholar : PubMed/NCBI
11	Busto R, Schally AV, Varga JL, et al: The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA. 99:11866–11871. 2002. View Article : Google Scholar : PubMed/NCBI
12	Chatzistamou I, Schally AV, Kiaris H, et al: Immunohisto-chemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur J Endocrinol. 151:391–396. 2004. View Article : Google Scholar : PubMed/NCBI
13	Engel JB, Keller G, Schally AV, et al: Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab. 90:3614–3621. 2005. View Article : Google Scholar : PubMed/NCBI
14	Frohman LA and Szabo M: Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res. 74:259–271. 1981.PubMed/NCBI
15	Garcia-Fernandez MO, Schally AV, Varga JL, Groot K and Busto R: The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat. 77:15–26. 2003. View Article : Google Scholar
16	Guo J, Schally AV, Zarandi M, Varga J and Leung PC: Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol. 8:542010. View Article : Google Scholar : PubMed/NCBI
17	Kahán Z, Arencibia JM, Csernus VJ, et al: Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab. 84:582–589. 1999.PubMed/NCBI
18	Schally A and Varga JL: Antagonists of growth hormone-releasing hormone. Comb Chem High Throughput Screen. 9:163–170. 2006. View Article : Google Scholar : PubMed/NCBI
19	Schally AV, Comaru-Schally AM, Nagy A, et al: Hypothalamic hormones and cancer. Front Neuroendocrinol. 22:248–291. 2001. View Article : Google Scholar
20	Schally AV, Varga JL and Engel JB: Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 4:33–43. 2008. View Article : Google Scholar : PubMed/NCBI
21	Barabutis N, Siejka A, Schally AV, Block NL, Cai R and Varga L: Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. J Mol Endocrinol. 44:127–134. 2010. View Article : Google Scholar : PubMed/NCBI
22	Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A and Kiaris H: Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA. 104:5575–5579. 2007. View Article : Google Scholar : PubMed/NCBI
23	Havt A, Schally AV, Halmos G, et al: The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA. 102:17424–17429. 2005. View Article : Google Scholar : PubMed/NCBI
24	Rekasi Z, Czompoly T, Schally AV and Halmos G: Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA. 97:10561–10566. 2000. View Article : Google Scholar : PubMed/NCBI
25	Köster F, Engel JB, Schally AV, et al: Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat. 116:273–279. 2009.PubMed/NCBI
26	Pombo CM, Zalvide J, Gaylinn BD and Dieguez C: Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology. 141:2113–2119. 2000.PubMed/NCBI
27	Siriwardana G, Bradford A, Coy D and Zeitler P: Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol. 20:2010–2019. 2006. View Article : Google Scholar : PubMed/NCBI
28	Berchem GJ, Bosseler M, Mine N and Avalosse B: Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res. 19:535–540. 1999.
29	Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P and André S: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 22:3–16. 1995.
30	Buchholz S, Schally AV, Engel JB, et al: Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA. 104:1943–1946. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kovács M, Schally AV, Hohla F, et al: A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides. 31:1839–1846. 2010.PubMed/NCBI
32	Rick FG, Schally AV, Block NL, et al: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 71:736–747. 2011. View Article : Google Scholar
33	Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY and Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 98:1889–1892. 2007. View Article : Google Scholar : PubMed/NCBI
34	Eralp Y, Derin D, Ozluk Y, et al: MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 19:669–674. 2008. View Article : Google Scholar : PubMed/NCBI